vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Orange County Bancorp, Inc. (OBT). Click either name above to swap in a different company.

Orange County Bancorp, Inc. is the larger business by last-quarter revenue ($33.0M vs $19.6M, roughly 1.7× STANDARD BIOTOOLS INC.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -177.4%, a 215.0% gap on every dollar of revenue. On growth, Orange County Bancorp, Inc. posted the faster year-over-year revenue change (20.6% vs -11.5%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-23.1M). Over the past eight quarters, Orange County Bancorp, Inc.'s revenue compounded faster (14.3% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.

LAB vs OBT — Head-to-Head

Bigger by revenue
OBT
OBT
1.7× larger
OBT
$33.0M
$19.6M
LAB
Growing faster (revenue YoY)
OBT
OBT
+32.1% gap
OBT
20.6%
-11.5%
LAB
Higher net margin
OBT
OBT
215.0% more per $
OBT
37.6%
-177.4%
LAB
More free cash flow
OBT
OBT
$64.4M more FCF
OBT
$41.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
OBT
OBT
Annualised
OBT
14.3%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
OBT
OBT
Revenue
$19.6M
$33.0M
Net Profit
$-34.7M
$12.4M
Gross Margin
48.5%
Operating Margin
-168.5%
41.4%
Net Margin
-177.4%
37.6%
Revenue YoY
-11.5%
20.6%
Net Profit YoY
-28.8%
73.5%
EPS (diluted)
$-0.09
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
OBT
OBT
Q4 25
$33.0M
Q3 25
$19.6M
$33.7M
Q2 25
$21.8M
$32.5M
Q1 25
$40.8M
$28.0M
Q4 24
$27.4M
Q3 24
$22.1M
$27.1M
Q2 24
$22.5M
$27.9M
Q1 24
$45.5M
$25.3M
Net Profit
LAB
LAB
OBT
OBT
Q4 25
$12.4M
Q3 25
$-34.7M
$10.0M
Q2 25
$-33.5M
$10.5M
Q1 25
$-26.0M
$8.7M
Q4 24
$7.2M
Q3 24
$-26.9M
$3.2M
Q2 24
$-45.7M
$8.2M
Q1 24
$-32.2M
$9.3M
Gross Margin
LAB
LAB
OBT
OBT
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
OBT
OBT
Q4 25
41.4%
Q3 25
-168.5%
38.6%
Q2 25
-118.1%
41.9%
Q1 25
-80.8%
40.3%
Q4 24
32.8%
Q3 24
-120.9%
14.8%
Q2 24
-134.5%
36.6%
Q1 24
-132.2%
45.9%
Net Margin
LAB
LAB
OBT
OBT
Q4 25
37.6%
Q3 25
-177.4%
29.7%
Q2 25
-153.7%
32.2%
Q1 25
-63.8%
31.1%
Q4 24
26.2%
Q3 24
-122.0%
11.8%
Q2 24
-203.3%
29.4%
Q1 24
-70.6%
36.7%
EPS (diluted)
LAB
LAB
OBT
OBT
Q4 25
$0.94
Q3 25
$-0.09
$0.75
Q2 25
$-0.09
$0.87
Q1 25
$-0.07
$0.77
Q4 24
$0.64
Q3 24
$-0.07
$0.28
Q2 24
$-0.12
$0.73
Q1 24
$-0.27
$0.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
OBT
OBT
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$284.4M
Total Assets
$539.6M
$2.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
OBT
OBT
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
OBT
OBT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
OBT
OBT
Q4 25
$284.4M
Q3 25
$399.7M
$270.1M
Q2 25
$424.5M
$252.6M
Q1 25
$454.6M
$201.3M
Q4 24
$185.5M
Q3 24
$489.3M
$193.1M
Q2 24
$510.3M
$177.5M
Q1 24
$577.3M
$168.7M
Total Assets
LAB
LAB
OBT
OBT
Q4 25
$2.7B
Q3 25
$539.6M
$2.6B
Q2 25
$557.0M
$2.6B
Q1 25
$579.6M
$2.6B
Q4 24
$2.5B
Q3 24
$681.5M
$2.5B
Q2 24
$708.7M
$2.5B
Q1 24
$777.7M
$2.5B
Debt / Equity
LAB
LAB
OBT
OBT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
OBT
OBT
Operating Cash FlowLast quarter
$-22.2M
$43.8M
Free Cash FlowOCF − Capex
$-23.1M
$41.3M
FCF MarginFCF / Revenue
-118.1%
125.1%
Capex IntensityCapex / Revenue
4.5%
7.6%
Cash ConversionOCF / Net Profit
3.53×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$69.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
OBT
OBT
Q4 25
$43.8M
Q3 25
$-22.2M
$30.2M
Q2 25
$-20.7M
$-5.0M
Q1 25
$-30.3M
$4.8M
Q4 24
$34.6M
Q3 24
$-27.9M
$10.2M
Q2 24
$-39.0M
$9.3M
Q1 24
$-62.5M
$2.3M
Free Cash Flow
LAB
LAB
OBT
OBT
Q4 25
$41.3M
Q3 25
$-23.1M
$29.6M
Q2 25
$-22.6M
$-5.7M
Q1 25
$-35.3M
$4.3M
Q4 24
$32.9M
Q3 24
$-30.1M
$10.0M
Q2 24
$-41.0M
$9.2M
Q1 24
$-63.3M
$2.0M
FCF Margin
LAB
LAB
OBT
OBT
Q4 25
125.1%
Q3 25
-118.1%
87.8%
Q2 25
-103.6%
-17.5%
Q1 25
-86.6%
15.5%
Q4 24
120.0%
Q3 24
-136.4%
36.7%
Q2 24
-182.2%
32.8%
Q1 24
-138.9%
7.9%
Capex Intensity
LAB
LAB
OBT
OBT
Q4 25
7.6%
Q3 25
4.5%
1.8%
Q2 25
8.7%
2.3%
Q1 25
12.4%
1.8%
Q4 24
6.3%
Q3 24
10.2%
1.1%
Q2 24
8.6%
0.4%
Q1 24
1.7%
1.0%
Cash Conversion
LAB
LAB
OBT
OBT
Q4 25
3.53×
Q3 25
3.01×
Q2 25
-0.47×
Q1 25
0.56×
Q4 24
4.83×
Q3 24
3.19×
Q2 24
1.13×
Q1 24
0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

OBT
OBT

Segment breakdown not available.

Related Comparisons